HER2 + BREAST CANCER

This study tests whether combining two experimental drugs (HLX22 and HLX87) works better than standard care as the first treatment for people with HER2-positive breast cancer that has returned or spread. About 706 adults with advanced disease will participate. The main goals are …

This early-phase trial tests an experimental drug called IAM1363 in people with advanced cancers that have HER2 alterations. The study aims to find a safe dose and see if the drug can shrink tumors, including those that have spread to the brain. About 383 adults whose cancer has …

This study tests a new drug called PC14586 (rezatapopt) in people with advanced or spreading solid tumors that have a specific change in the TP53 gene (Y220C mutation). The goal is to see if the drug is safe and works against these cancers. About 300 adults (and some teens after …

This study compares two treatments for advanced estrogen receptor-positive (ER+) breast cancer that has stopped responding to standard therapies. About 297 participants will receive either a combination of elacestrant and capecitabine or capecitabine alone. The goal is to see if …

This study tests a new drug combination (trastuzumab deruxtecan plus pertuzumab) given before surgery to shrink tumors in people with HER2-positive breast cancer. If the tumor shrinks enough, they continue the same drugs; if not, they switch to another combo. The goal is to see h…

This study tests whether giving a precise, high-dose radiation treatment (SBRT) to a single spot where breast cancer has worsened can help keep the disease from spreading further. About 46 adults with metastatic breast cancer (ER+ or HER2+) will continue their usual drug therapy …

This early-stage trial tests a new radioactive drug called [177Lu]Lu-ABY-271 in people with HER2-positive metastatic breast cancer that cannot be removed by surgery. The main goals are to check safety and see where the drug goes in the body. About 21 participants will take part.

This study looks at whether a simple blood test can find tiny bits of cancer DNA left in the body after breast cancer treatment. Finding this DNA, called minimal residual disease, may help predict if the cancer will come back. The study will follow 900 people with different types…

This study follows 1,000 people with HER2-positive breast cancer to see how patient and tumor features affect survival and treatment response. Researchers will track 5-year survival rates and how often tumors disappear completely after pre-surgery therapy. The goal is to gather k…

This study is for 500 adults with breast cancer who are about to start treatment like chemotherapy or immunotherapy before surgery. Researchers will collect tumor tissue, blood, and sometimes MRI scans and stool samples during treatment. The goal is to learn why some cancers shri…